



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2024-25/136
March 7, 2025

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Ref: Announcement dated March 6, 2025 – Administrative warning letter

This is in continuation to the intimation dated March 6, 2025 bearing reference no. ADL/SE/2024-25/135 and additional details asked by National Stock Exchange of India Limited (NSE), pursuant to Industry Standards Note on Regulation 30 of the Listing Regulations, by email dated March 7, 2025, I, the undersigned, state and declare that the information and details provided in Form A, in compliance with Regulation 30(13) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, is true, correct and complete to the best of my knowledge and belief.

This is for your information and records.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: F12932

**Aarti Drugs Limited**

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Form A**Disclosure by Aarti Drugs Limited regarding receipt of communication from regulatory, statutory, enforcement or judicial authority under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

[Regulation 30(13) – Disclosure of communication from regulatory, statutory, enforcement or judicial authority]

Sr. No.	Particulars	Details
1.	Name of the listed company	Aarti Drugs Limited
2.	Type of communication received	Administrative warning letter
3.	Date of receipt of communication	March 6, 2025
4.	Authority from whom communication received	Securities and Exchange Board of India (SEBI)
5.	Brief summary of the material contents of the communication received, including reasons for receipt of the communication	The Company Secretary & Compliance Officer has received an Administrative Warning letter issued by Deputy General Manager, Investigation Department of SEBI for violation of SEBI (Prohibition of Insider Trading) Regulations, 2015 in connection with investigation into trading activities of certain entities in the script of Aarti Drugs Limited.
6.	Period for which communication would be applicable, if stated	N.A
7.	Expected financial implications on the listed company, if any	There is no financial impact on the Company.
8.	Details of any aberrations/non-compliances identified by the authority in the communication	As per administrative warning letter; <ul style="list-style-type: none">- Company did not take adequate steps to obtain requisite details and identify all the immediate relatives of the Designated Persons of the Company.- Code of Conduct on PIT was not made applicable to the certain immediate relatives of designated persons.
9.	Details of any penalty or restriction or sanction imposed pursuant to the communication	There is no penalty or restriction or sanction imposed.
10.	Action(s) taken by listed company with respect to the communication	The Company shall ensure compliance with the regulation and exercise due caution to avoid recurrence of such events.
11.	Any other relevant information	-